The objective of this study was to determine whether recombinant human cytochrome P450 1B1 (rhCYP1B1) metabolizes the anticancer agent docetaxel (Taxotere) in vitro. First, the catalytic activities of Supersomes-expressed rhCYP1B1 toward 17␤-estradiol and of rhCYP3A4 toward docetaxel in our conditions were determined. Second, [
Docetaxel (Taxotere) is a major chemotherapeutic molecule with particular potency against breast cancers. Its mechanism of cytotoxicity is thought to be related to its ability to alter tubulin processing within the cells; docetaxel increases the rate of tubulin polymerization and inhibits the depolymerization of microtubules. Docetaxel is metabolized by CYP3A4-and CYP3A5-mediated oxidations (Shou et al., 1998) . Recently, a decrease of the in vitro cytotoxic potency of docetaxel was observed in Chinese hamster ovary cells transfected with human cytochrome P450 1B1 (hCYP1B1 1 ). In addition, this effect was reversed in the presence of ␣-naphthoflavone, an inhibitor of hCYP1B1 (McFadyen et al., 2001) . The authors concluded that hCYP1B1 expression could be a mechanism of tumor resistance to docetaxel, and they referred to preliminary studies showing that docetaxel was metabolized by hCYP1B1. However, this was not exactly the case. In fact, these earlier studies only showed that docetaxel was a competitive inhibitor of the hCYP1B1-mediated ethoxyresorufin O-deethylation, with a K i of 28 M (Rochat et al., 2001 ). Since CYP1B1 is expressed in a wide variety of human tumors (Murray et al., 1997) , it was considered necessary to have direct evidence of its possible catalytic activity on docetaxel.
Materials and Methods
Chemicals. ␣-Naphthoflavone, 17␤-estradiol, ethoxyresorufin, NADPH, EDTA, ascorbic acid, and reduced glutathione were purchased from SigmaAldrich (St. Louis, MO). [
14 C]docetaxel was purchased from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). 2-Chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine 1-carboxamide (CMV423; Bournique et al., 2001 ) was synthesized at the Centre de Recherche de Vitry-Alfortville, Aventis Pharma, (Vitry-Alfortville, France).
Enzymes. Recombinant human cytochrome P450 1B1 (rhCYP1B1) and 3A4 (rhCYP3A4) expressed in insect cells (Supersomes) were purchased from BD Gentest Corporation (Woburn, MA). The specific contents were 138.9 and 208.3 pmol P450/mg of microsomal protein, respectively. The cytochrome c reductase activity of the coexpressed human NADPH P450 reductase was 260 and 3500 nmol/min/mg, respectively. Human cytochrome b 5 was also coexpressed with rhCYP3A4, at a specific content of 1200 pmol/mg. The activities of rhCYP1B1 and 3A4 are shown in Table 1 . Purification of rabbit liver cytochrome b 5 was performed as described by Strittmatter et al., 1978. Incubations. 17␤-Estradiol in methanol was incubated at 1 M, final concentration, in the presence of 25 pmol/ml of rhCYP1B1 Supersomes with 1 mM NADPH and 2 mM ascorbic acid, in 0.1 M phosphate buffer, pH 7.4, at 37°C in a shaking water bath, up to 60 min. The concentration of methanol in the incubations was 0.5%. The reaction was stopped by the addition of 1 volume of methanol/acetonitrile 60:40 (v/v) with 6% perchloric acid. Supernatants were analyzed by HPLC with fluorescence detection.
[ 14 C]docetaxel, in methanol, was incubated at 0.1, 1, or 30 M, final concentrations, in the presence of 25 pmol/ml of rhCYP1B1 and with 1 mM NADPH, in 0.1 M phosphate buffer, pH 7.4, at 37°C in a shaking water bath. The incubation lasted 30 min in the statistical design and 60 min in the other experiments. The concentration of methanol in the incubations was 0.5%. Reactions were terminated by the addition of 1 volume of methanol. After centrifugation, supernatants were analyzed by HPLC. Alternatively, [ 14 C]docetaxel was incubated as described above in the presence of potential P450 activators, namely CMV423 (Bournique et al., 2001 ) at 10 and 100 M, final concentrations, ␣-naphthoflavone at 3, 10, 30, and 100 M, final concentrations, acetonitrile, ethanol, methanol, and DMSO at 2%, final concentration. These compounds were added with [
14 C]docetaxel before the start of the reaction with NADPH. In the statistical experimental design, [ 14 C]docetaxel in the presence of 25 pmol/ml of rhCYP1B1 was incubated in 16 different combinations of 10 incubation factors, using a fractional factorial design. The incubation factors were the docetaxel (1 and 30 M), the buffer (25 and 100 mM), and the NADPH (0.6 and 2 mM) concentration, the buffer type (phosphate and Tris), the starting mode of the reaction (NADPH and cold microsomes), and the presence of magnesium (0; 10 mM), cytochrome b 5 (0; 50 pmol/ml), EDTA (0; 1 mM), ascorbic acid (0; 2 mM), and reduced glutathione (0; 5 mM).
Inhibitions of 7-ethoxyresorufin O-deethylase activity (EROD) were measured as follows. rhCYP1B1 (5 pmol) in 1 ml 0.1 M phosphate buffer, pH 7.4, containing 1 mM NADPH were preincubated under agitation at 37°C during 1 min in glass tubes, in the presence of 1 M ␣-naphthoflavone or in the presence of 0, 3, 10, 30, and 100 M docetaxel or 7-epidocetaxel. The reactions were started by the addition of 1 M 7-ethoxyresorufin and allowed to proceed during 2 min. Stock solutions of substrates and inhibitors were in DMSO. The total final concentration of DMSO was 1% in all incubations. Reactions were stopped by the addition of 1 ml of cold phosphate buffer 0.1 M, pH 7.4, containing 1% DMSO, vortex and kept on ice. After centrifugation at 4°C, supernatants were assayed for resorufin. Resorufin was measured by fluorescence on a SFM KONTRON (Saint Quentin en Yvelines, France), using a calibration of 100 mFAU for 0.25 M resorufin. The fluorescence of resorufine was not modified in the presence of docetaxel and 7-epidocetaxel, whatever their concentration. Preliminary measurements by on-line fluorescence kinetics indicated that all the reactions were linear within the two first minutes. Surprisingly, when 7-ethoxyresorufin was preincubated in the presence of docetaxel, and the reactions started by the addition of NADPH, although the kinetics were still linear during 2 min, highly variable results were repeatedly obtained within each triplicate, showing either activation or inhibition of the rhCYP1B1-mediated EROD activity.
HPLC Analysis. Supernatants of 17␤-estradiol incubations were analyzed on a C 18 Hypersil BDS column (Hypersil, Runcorn, Cheshire, UK). Chromatography was effected using a mobile phase of water/methanol/acetonitrile (40:40:20 with 0.05% trifluoroacetic acid) at a flow rate of 0.6 ml/min. The retention times of 4-hydroxyestradiol, 2-hydroxyestradiol, and estradiol were 6, 6.7, and 8.6 min, respectively.
Supernatants of [ 14 C]docetaxel incubations were analyzed by reverse phase gradient HPLC with radiodetection (limit of quantification, 5 nM) as previously described (Marre et al., 1996) . Data Analysis. Rates of metabolism were calculated with GraFit software, Sigma-Aldrich. The statistical experimental design was built, analyzed, and validated with JMP (Cary, NC) and Modde (Umea, Sweden) software packages, as previously described (Bournique et al., 1999) . Analyses of the results were performed by multilinear regression.
Results and Discussion
In the first instance, the activity of the preparation of rhCYP1B1 was measured on a prototypic substrate, 17␤-estradiol. As shown in Fig. 1 and Table 1 , rhCYP1B1 metabolized 17␤-estradiol (1 M) in our incubation conditions with an initial rate of 2.3 min Ϫ1 and a 4-hydroxyestradiol/2-hydroxyestradiol ratio of 5, in agreement with previous studies (Hanna et al., 2000; Li et al., 2000) . In the second instance, the metabolism of docetaxel by Supersomes-expressed P450s in our incubation conditions was studied. As shown in Fig. 2 and Table 1 , docetaxel was significantly metabolized by rhCYP3A4 Supersomes, as expected. The metabolism of docetaxel by rhCYP1B1 was then studied. When [ 14 C]docetaxel at 0.1 and 1 M was repeatedly incubated up to 60 min with rhCYP1B1, no metabolism of docetaxel was detected. It was then decided to investigate other rhCYP1B1/docetaxel incubation conditions. The effect of some P450 isoenzymes activators, namely CMV423 (Bournique et al., 1999) , ␣-naphthoflavone, and organic solvents (see Materials and Methods) was tested. Recombinant hCYP1B1 did not metabolize docetaxel in the presence of any of these potential activators. Therefore, the effect of 10 incubation factors on the activity of rhCYP1B1 on docetaxel was studied. These factors were the docetaxel concentration, the buffer type, the buffer concentration, the presence of magnesium, the presence of rabbit liver purified cytochrome b 5 , the starting mode of the reaction, the NADPH concentration, and the presence of EDTA, ascorbic acid, and reduced glutathione. Two levels were selected for each factor, as indicated under Materials and Methods. Studying all the factor combinations would have needed 1024 (2 10 ) assays. A fractional factorial design of only 16 factor combinations was used to rapidly and efficiently detect the factors that could be important for an activity of rhCYP1B1 toward docetaxel. When these experiments were performed, again, no metabolism of docetaxel was detected.
However, 7-epidocetaxel was detected in some experiments. 7-Epidocetaxel is an epimer of docetacel that is formed from docetaxel when docetaxel is in solution. The concentrations of 7-epidocetaxel 
Catalytic activities of recombinant human CYP1B1 and 3A4
7-ethoxyresorufin O-deethylase activity (EROD) was measured in 0.1 M phosphate buffer, pH 7.4, containing 10 pmol rhCYP1B1/ml and 1.3 mM NADP ϩ , 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, and 3.3 mM magnesium chloride. 17␤-estradiol biotransformation was measured in 0.1 M phosphate buffer, pH 7.4, containing 25 pmol CYP1B1/ml, 2 mM ascorbic acid, and 1 mM NADPH. Testosterone 6␤-hydroxylase activity was measured in the same conditions as EROD, using 20 pmol CYP3A4/ml. Docetaxel biotransformation was measured in the same conditions as 17␤-estradiol, except that ascorbic acid was omitted in the case of CYP3A4. 
FIG. 1. Metabolism of estradiol by recombinant hCYP1B1.
Estradiol concentration was 1 M. Recombinant hCYP1B1 (Supersomes) concentration was 25 pmol/ml. Incubation was performed during 60 min in 0.1 M phosphate buffer, pH 7.4, at 37°C, with 1 mM NADPH and 2 mM ascorbic acid. HPLC analysis is described under Materials and Methods. E2, 17␤-estradiol; 4-OH, 4-hydroxyestradiol; 2-OH, 2-hydroxyestradiol. The arrow indicates a presteady state period of 5 min.
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org are usually very low as compared with those of docetaxel. In the present experiments, 7-epidocetaxel was detected when the concentration of docetaxel was high, and it was already present at the start of the reaction (t 0 ). After 30 min of incubation, the concentration of 7-epidocetaxel either increased, decreased, or maintained relatively to the experiments. The analysis of the effects of the factors on the concentration of 7-epidocetaxel was performed by multilinear regression. No significant effects were found to explain the variation of 7-epidocetaxel from 0 to 30 min of incubation, but significant effects ( p Ͻ 0.05) were detected relatively to the concentration of 7-epidocetaxel at t 0 (Fig. 3) . The significantly influential factors were docetaxel concentration, buffer type, and glutathione. More precisely, the docetaxel concentration of 30 M, the phosphate buffer, and the absence of glutathione increased the concentration of 7-epidocetaxel at t 0 . None of the other tested factors were influential. As a next step, 1 M 7-epidocetaxel was incubated with rhCYP1B1 in the standard conditions described above for docetaxel, to test if docetaxel could be metabolized by rhCYP1B1 via 7-epidocetaxel. No metabolism of 7-epidocetaxel was detected either. As a final step, the effect of docetaxel and 7-epidocetaxel on the rhCYP1B1-mediated EROD activity was studied, to evaluate if these molecules can bind to rhCYP1B1 in our conditions. Results are shown in Table 2 . ␣-Napthoflavone (1 M), used as a control inhibitor, totally abolished the rhCYP1B1-mediated EROD activity, as expected. Docetaxel at 3 M had no significant effect on the rhCYP1B1-mediated EROD activity. At the concentrations of 10 and 30 M, docetaxel increased and decreased the activity by 30 and 22%, respectively. At 100 M, docetaxel increased by 3.8-fold the rhCYP1B1-mediated EROD activity, showing a marked activatory effect. 7-Epidocetaxel at 3 M had no significant effect on the rhCYP1B1-mediated EROD activity. At 10, 30, and 100 M, 7-epidocetaxel increased the activity by Ͼ7-, 4.8-, and 4.7-fold, respectively, showing 7-epidocetaxel as a potent CYP1B1 activator. These results are in complete contradiction to those of Rochat et al. (2001) who found that docetaxel competitively inhibited rhCYP1B1-mediated EROD activity with a K i of 28 M. Possibly, the differing incubation conditions could explain this discrepancy. For example, Rochat et al. used 10 mM MgCl 2 in their incubation medium, whereas we did not add any MgCl 2 in our own incubations. It has been shown that the concentration of divalent cations has dramatic influences on the kinetics of cytochrome P450s, particularly on CYP3A4 (Peters and Fouts, 1970; Gillam et al., 1995; Yamazaki et al., 1995; Bournique et al., 1999) . In addition, the design of the interaction experiment influenced the effect of docetaxel on the rhCYP1B1-mediated EROD activity (see Methods and Materials), which may also explain the discrepancy between the studies. On the whole, this last experiment demonstrated 1-that docetaxel and 7-epidocetaxel can bind to rhCYP1B1 and 2-that they are effectors of rhCYP1B1 in vitro.
In conclusion, docetaxel was not metabolized in vitro by recombinant human CYP1B1 expressed in Supersomes. Several hypothesis can be proposed, therefore, to explain the protective effect of transfected hCYP1B1 on docetaxel-exposed Chinese hamster ovary cells
FIG. 2. Metabolism of docetaxel by recombinant hCYP3A4.
Docetaxel concentration was 1 M. Recombinant hCYP3A4 (Supersomes) concentration was 50 pmol/ml. Incubation was performed during 60 min in 0.1 M phosphate buffer, pH 7.4, at 37°C, with 1 mM NADPH. HPLC analysis is described under Materials and Methods. Peaks 1, 2, 3, and 4, oxidative metabolites of docetaxel (Marre F. et al., 1996) .
FIG. 3. Effects of 10 factors on the concentration of 7-epidocetaxel at t 0 of the incubation.
The effects were calculated by multilinear regression. N.S., not significant at p ϭ 0.05.
TABLE 2

Effect of ␣-naphthoflavone, docetaxel and 7-epidocetaxel on rhCYP1B1-mediated EROD activity in vitro
Effects are given in % of controls without inhibitors (vehicle only) as means (S.D.) of triplicate. 7-ethoxyresorufin O-deethylase activity (EROD) was measured in 0.1 M phosphate buffer pH 7.4, containing 5 pmol rhCYP1B1/mL, 1 mM NADPH, and the molecule to bested. After 1-min preincubation at 37°C, reactions were started by the addition of ethoxyresorufin, 1 M. Substrate and inhibitors were added in DMSO (1%, total final concentration). Reactions were stopped after 2-min incubation at 37°by the addition of 1 ml cold phosphate buffer 0.1 M, pH 7.4, containing 1% DMSO, vortex and kept on ice. After centrifugation at 4°C, the concentration of resorufin in the supernatants was measured with a spectrofluorimeter, using a calibration with reference resorufin. 
Concentration
